There is no effective treatment with a high success rate against coronavirus. Moreover, the testing of an experimental treatment has just been suspended.
Late yesterday, pharmaceutical group Eli Lilly announced that it was suspending the clinical trial of its experimental antibody treatment against Coronavirus infections for safety reasons. As usual, in such situations, the level of transparency of the manufacturing company is not very high, because any negative statement may be reflected in a sharp decrease in the value of traded shares. on the stock exchange. Ideally, it should be limited to just a few essential words to get the message across.
“We know that, as a precautionary measure, the independent health monitoring committee in the ACTIV-3 process has recommended a break in recruitment,” a spokesman told AFP. a trial involving hospitalized Covid-19 patients. Lilly supports the decision of the independent committee to ensure the safety of patients participating in the study, it is also shown in the same statement.
As a reference, we are talking about a treatment similar to the one given to Donald Trump, shortly after the onset of symptoms of Covid-19 infection. Eli Lilly develops synthetic antibodies that can be administered intravenously. They are manufactured to neutralize the coronavirus responsible for the condition that has led to over one million deaths globally.
The difference is that Donald Trump benefited from monoclonal antibodies developed by the Regeneron company, which are also in an experimental testing stage. No such treatment has been certified by any medical authority for widespread use.
Eli Lilly and Regeneron approached the US Drug Agency (FDA) last week for urgent approval of their treatments. However, the process is a long one, and the FDA must first check its safety and the possibility of serious side effects.
It is unclear at this time whether the suspension of synthetic antibody treatments will affect other companies, such as Regeneron or just Eli Lilly, who issued a press release on the subject.